CN110998318A - 基于转移性疾病中循环肿瘤细胞(ctc)的单细胞表征的确定疗法的方法 - Google Patents

基于转移性疾病中循环肿瘤细胞(ctc)的单细胞表征的确定疗法的方法 Download PDF

Info

Publication number
CN110998318A
CN110998318A CN201880050607.7A CN201880050607A CN110998318A CN 110998318 A CN110998318 A CN 110998318A CN 201880050607 A CN201880050607 A CN 201880050607A CN 110998318 A CN110998318 A CN 110998318A
Authority
CN
China
Prior art keywords
ctc
ctcs
cancer
biomarker
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880050607.7A
Other languages
English (en)
Chinese (zh)
Inventor
瑞安·迪塔莫尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epic Sciences Inc
Original Assignee
Epic Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epic Sciences Inc filed Critical Epic Sciences Inc
Publication of CN110998318A publication Critical patent/CN110998318A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880050607.7A 2017-06-02 2018-06-01 基于转移性疾病中循环肿瘤细胞(ctc)的单细胞表征的确定疗法的方法 Pending CN110998318A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762514642P 2017-06-02 2017-06-02
US62/514,642 2017-06-02
US201762531725P 2017-07-12 2017-07-12
US62/531,725 2017-07-12
PCT/US2018/035581 WO2018222979A1 (en) 2017-06-02 2018-06-01 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease

Publications (1)

Publication Number Publication Date
CN110998318A true CN110998318A (zh) 2020-04-10

Family

ID=64455086

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880050607.7A Pending CN110998318A (zh) 2017-06-02 2018-06-01 基于转移性疾病中循环肿瘤细胞(ctc)的单细胞表征的确定疗法的方法

Country Status (8)

Country Link
US (2) US20220260574A1 (https=)
EP (1) EP3631445B1 (https=)
JP (2) JP2020522697A (https=)
CN (1) CN110998318A (https=)
AU (1) AU2018275265A1 (https=)
CA (1) CA3065316A1 (https=)
IL (1) IL270974A (https=)
WO (1) WO2018222979A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114092934A (zh) * 2020-07-31 2022-02-25 骏实生物科技(上海)有限公司 循环肿瘤细胞的分类方法
CN114594252A (zh) * 2020-12-03 2022-06-07 复旦大学附属中山医院 循环肿瘤细胞形态学特征在胃癌临床诊疗中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225753A2 (en) * 2019-05-06 2020-11-12 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN113826169A (zh) * 2019-05-14 2021-12-21 匹兹堡大学高等教育联邦体系 用于根据多参数细胞和亚细胞成像数据表征细胞表型多样性的系统和方法
WO2021108043A1 (en) * 2019-11-27 2021-06-03 University Of Cincinnati Assessing treatment response with estimated number of tumor cells
AU2021207312A1 (en) * 2020-01-17 2022-06-30 Universität Zürich Single cell pathology analysis of tumour samples
JP7836038B2 (ja) * 2020-12-10 2026-03-26 国立大学法人信州大学 メラノーマ患者の治療効果を判定する方法
US20240054640A1 (en) * 2020-12-15 2024-02-15 Carnegie Mellon University System, Method, and Computer Program Product for Classification of Diseases Based on Expansion Microscopic Images
EP4060319A1 (en) 2021-03-12 2022-09-21 Sysmex Corporation Analysis method and analyzer
JP7824031B2 (ja) * 2021-03-12 2026-03-04 シスメックス株式会社 分析方法および分析装置
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112955A1 (en) * 2014-01-27 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
US20150212089A1 (en) * 2014-01-30 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies
CN105636594A (zh) * 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
US20160266127A1 (en) * 2013-09-30 2016-09-15 Peter Kuhn Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
WO2016196284A1 (en) * 2015-05-29 2016-12-08 Epic Sciences, Inc. Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033114A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105636594A (zh) * 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
US20160266127A1 (en) * 2013-09-30 2016-09-15 Peter Kuhn Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
CN106062561A (zh) * 2013-09-30 2016-10-26 斯克利普斯研究院 为了监测前列腺癌患者中的肿瘤进化进行循环肿瘤细胞的基因型和表型分析
WO2015112955A1 (en) * 2014-01-27 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for prostate cancer biomarkers
US20150212089A1 (en) * 2014-01-30 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies
WO2016196284A1 (en) * 2015-05-29 2016-12-08 Epic Sciences, Inc. Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. BELTRAN ET AL: "The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cance", CLINICAL CANCER RESEARCH, vol. 22, no. 6, pages 1510 - 1519, XP055382275, DOI: 10.1158/1078-0432.CCR-15-0137 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114092934A (zh) * 2020-07-31 2022-02-25 骏实生物科技(上海)有限公司 循环肿瘤细胞的分类方法
CN114594252A (zh) * 2020-12-03 2022-06-07 复旦大学附属中山医院 循环肿瘤细胞形态学特征在胃癌临床诊疗中的应用
WO2022117081A1 (zh) * 2020-12-03 2022-06-09 复旦大学附属中山医院 循环肿瘤细胞形态学特征在胃癌临床诊疗中的应用

Also Published As

Publication number Publication date
EP3631445A1 (en) 2020-04-08
JP2020522697A (ja) 2020-07-30
EP3631445B1 (en) 2024-09-25
US20220260574A1 (en) 2022-08-18
EP3631445A4 (en) 2021-05-26
AU2018275265A1 (en) 2020-01-30
CA3065316A1 (en) 2018-12-06
WO2018222979A1 (en) 2018-12-06
US20250155440A1 (en) 2025-05-15
JP2023120213A (ja) 2023-08-29
IL270974A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US20220390451A1 (en) Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
US20250155440A1 (en) Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease
US20230033449A1 (en) Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)
US20250180564A1 (en) Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
US20200333345A1 (en) Circulating tumor cell diagnostics for prostate cancer biomarkers
US20220091124A1 (en) Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies
CN107250796B (zh) 用于鉴别对雄激素受体靶向疗法的抵抗性的循环肿瘤细胞诊断

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200410